Impaired residual renal function predicts denosumab-induced serum calcium decrement as well as increment of bone mineral density in non-severe renal insufficiency
ConclusionsBoth low eGFR and high bone turnover were independent risk factors for denosumab-induced cCa decrement, and for increases in BMD. Pretreatment with antiresorptive agents may reduce the risk of hypocalcemia.
Source: Osteoporosis International - Category: Orthopaedics Source Type: research
More News: Calcium | Chronic Kidney Disease | Orthopaedics | Osteoporosis | Study | Urology & Nephrology | Xgeva